DLBCL

News

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.

News

Approval moves Columvi earlier in DLBCL treatment pathway

Roche has claimed a first-in-class approval in the EU for Columvi in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

News

MSD starts pivotal trial of ROR1 drug in first-line lymphoma

MSD has started a phase 3 trial of ROR1-directed ADC zilo-V as a treatment for previously untreated diffuse large B-cell lymphoma.

News

ASH: MSD’s ROR1 drug hits the target in first-line lymphoma

The results of a phase 2 trial of MSD’s anti-ROR1 ADC zilovertamab vedotin back up the company's decision to start a phase 3 trial in DLBCL.

News

After FDA no, Regeneron gets yes from EU on odronextamab

Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US.

News

After ph3 win, Roche eyes earlier use of Columvi in DLBCL

Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

Approval moves Columvi earlier in DLBCL treatment pathway

MSD starts pivotal trial of ROR1 drug in first-line lymphoma

ASH: MSD’s ROR1 drug hits the target in first-line lymphoma

After FDA no, Regeneron gets yes from EU on odronextamab

After ph3 win, Roche eyes earlier use of Columvi in DLBCL

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

DLBCL

Editor's Picks